Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00 2022-09-28 pm EDT
3.160 USD   +1.94%
09/13Invivyd, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2022 09/23/2022 09/26/2022 09/27/2022 09/28/2022 Date
3.27(c) 2.97(c) 3.16(c) 3.1(c) 3.16 Last
365 975 360 031 269 590 292 248 290 487 Volume
-0.61% -9.17% +6.40% -1.90% +1.94% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -262 M - -
Net cash position 2022 381 M - -
P/E ratio 2022 -1,29x
Yield 2022 -
Sales 2023 10,2 M - -
Net income 2023 -234 M - -
Net cash position 2023 175 M - -
P/E ratio 2023 -1,56x
Yield 2023 -
Capitalization 337 M 337 M -
EV / Sales 2022 -
EV / Sales 2023 15,9x
Nbr of Employees 102
Free-Float 66,6%
More Financials
Company
Invivyd, Inc., formerly Adagio Therapeutics, Inc., is a biopharmaceutical company. The company is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered... 
More about the company
Ratings of Invivyd, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about INVIVYD, INC.
09/13Invivyd, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial..
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
09/12Adagio Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
GL
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
CI
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
GL
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
AQ
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
AQ
08/19Insider Buy: Adagio Therapeutics
MT
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15Adagio Therapeutics : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
More news
News in other languages on INVIVYD, INC.
09/13Invivyd, Inc. a changé son ticker d'ADGI à IVVD
09/12Invivyd annonce de multiples candidats anticorps COVID-19 de nouvelle génération et sél..
08/19Achats d'initiés : Adagio Therapeutics
08/15Adagio Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le semest..
08/15La perte nette d'Adagio Therapeutics au deuxième trimestre diminue
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
ETFs positioned on INVIVYD, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.86%-8.13%United_States
ETFMG Treatments Testing and Advancements E...0.43%-8.41%-NC
ALPS Medical Breakthroughs ETF - USD0.22%-8.61%United_States
IShares Micro-Cap ETF - USD0.04%-8.99%United_States
Vanguard Russell 2000 Value ETF - USD0.01%-8.47%United_States
More ETFs positioned on INVIVYD, INC.
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 3,10 $
Average target price 3,83 $
Spread / Average Target 23,7%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-57.30%337
GILEAD SCIENCES, INC.-13.74%78 135
REGENERON PHARMACEUTICALS, INC.10.05%73 350
VERTEX PHARMACEUTICALS29.66%70 983
BIONTECH SE-50.48%31 021
WUXI APPTEC CO., LTD.-39.08%28 544